Regional lymph node involvement in malignant extremity soft-tissue sarcoma varies substantially depending on the histologic subtype of the tumor, according to an observational analysis of registry records from the Surveillance, Epidemiology, and End Results program. Although spread to regional lymph nodes is uncommon overall among patients presenting with soft-tissue sarcomas of the extremities, investigators found that specific histological classifications carry markedly different frequencies of nodal disease and that nodal positivity remains linked to reduced cancer-specific survival.
To evaluate these histology-specific patterns and their prognostic implications, researchers analyzed malignant extremity soft-tissue sarcoma cases diagnosed between 2018 and 2023. The cohort was derived using an audited, reproducible International Classification of Diseases for Oncology, Third Edition morphology code set. The investigation was designed to clarify contemporary rates of regional nodal involvement across distinct tumor types and to determine how nodal disease tracks with survival outcomes in recorded clinical practice.
Across the identified population, the researchers evaluated a total of 9,311 eligible cases of extremity soft-tissue sarcoma. Among these patients, 8,636 individuals had documented nodal status available for evaluation in the registry. Within this evaluated group, 376 patients, representing 4.4 percent of those with known nodal status, were identified as having regional node-positive disease, confirming that regional nodal presentation is relatively infrequent across the overall extremity sarcoma population.
The frequency of regional lymph node positivity differed sharply when the cohort was broken down by specific histologic subtypes. Recorded nodal positivity was highest among patients diagnosed with rhabdomyosarcoma at 30.9 percent, followed closely by clear cell sarcoma at 29.0 percent. Patients with epithelioid sarcoma demonstrated a 20.8 percent rate of nodal involvement, while those with angiosarcoma presented with a 13.7 percent rate of regional nodal positivity.
Multivariable logistic regression modeling was utilized to assess the adjusted odds of presenting with node-positive disease across the various histologic groups. In these adjusted comparisons, the odds of nodal involvement were highest for clear cell sarcoma, which demonstrated an adjusted odds ratio of 17.72. Rhabdomyosarcoma showed an adjusted odds ratio of 7.47, and epithelioid sarcoma showed an adjusted odds ratio of 6.82. In contrast, synovial sarcoma was not statistically associated with higher odds of nodal involvement relative to liposarcoma, yielding an odds ratio of 1.15 with a 95 percent confidence interval spanning 0.60 to 2.20.
The study also assessed the relationship between regional nodal involvement and cancer-specific survival using two Cox proportional hazards models and a Fine-Gray competing-risk analysis. In a tumor-adjusted Cox model, node-positive disease was associated with worse cancer-specific survival, yielding a hazard ratio of 1.46 with a 95 percent confidence interval ranging from 1.22 to 1.73. Following additional statistical adjustment for treatment factors, node-positive disease remained associated with poorer cancer-specific survival, showing an adjusted hazard ratio of 1.35 with a 95 percent confidence interval between 1.13 and 1.60.
To test the stability of the observed histology findings, the investigators conducted sensitivity analyses restricted to adult-only cases as well as nonmetastatic-only cases. The findings from these sensitivity analyses, alongside the competing-risk survival evaluations, were consistent with the primary results, demonstrating that the wide differences in nodal involvement across histological classifications were not driven solely by pediatric cases or distant metastatic spread at presentation.
The authors concluded that while recorded regional nodal involvement varies substantially by histologic subtype and correlates with worse cancer-specific survival, the observational data carry inherent limitations. The researchers emphasized that these observational registry findings support further clinical evaluation of histology-informed nodal assessment but do not establish that adopting any specific nodal staging strategy directly improves patient outcomes.
Subject of Research: Regional lymph node involvement and survival across histologic subtypes in extremity soft-tissue sarcoma
Article Title: Regional lymph node involvement varies by histologic subtype in extremity soft-tissue sarcoma
Article References: Alzahrani, M., Dabroom, A., & Alzahrani, Z. (2026). Regional lymph node involvement varies by histologic subtype in extremity soft-tissue sarcoma. Discover Oncology. https://doi.org/10.1007/s12672-026-06218-z
Image Credits: AI Generated
DOI: 10.1007/s12672-026-06218-z
Keywords: soft-tissue sarcoma, extremity sarcoma, lymph node involvement, histologic subtypes, clear cell sarcoma, rhabdomyosarcoma, epithelioid sarcoma, angiosarcoma, synovial sarcoma, liposarcoma, SEER database, cancer-specific survival, multivariable logistic regression, Cox proportional hazards, Fine-Gray competing risk, oncology registry analysis
News Source: Nathaniel Bowman. (November 13, 2026). Lymph Node Spread Varies Widely Across Soft-Tissue Sarcoma Types in Extremity Tumors. Scienmag.



